---
figid: PMC10838672__MCO2-5-e474-g005
figtitle: RTKs and its related downstream signaling pathways and their targeted therapies
  for hepatocellular carcinoma
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC10838672
filename: MCO2-5-e474-g005.jpg
figlink: /pmc/articles/PMC10838672/figure/F2
number: F2
caption: RTKs and its related downstream signaling pathways and their targeted therapies
  for hepatocellular carcinoma. The binding of RTKs to their corresponding growth
  factors can activate their protein kinase function, thereby regulating the downstream
  signal transduction pathways, expanding signal transduction and activating a series
  of biochemical reactions in cells. RTKIs are a hot spot in the research and development
  of antitumor drugs. At present, a variety of RTKIs related to HCC have entered phases
  I–III clinical trials and clinical use. EGFR, epidermal growth factor receptor;
  FGFR, fibroblast growth factor receptor; HGF, hepatocyte growth factor;c‐Met, cellular
  mesenchymal epithelial transition factor; IGFR, insulin‐like growth factor receptor;
  PDGFR, platelet‐derived growth factor receptor; RTKs, receptor tyrosine kinases;
  RTKIs, receptor tyrosine kinase inhibitors; PTEN, phosphatase and tensin homolog;
  PI3K, phosphoinositide 3 kinase
papertitle: 'Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy'
reftext: Xiaoting Luo, et al. MedComm (2020). 2024 Feb;5(2).
year: '2024'
doi: 10.1002/mco2.474
journal_title: MedComm
journal_nlm_ta: MedComm (2020)
publisher_name: John Wiley and Sons Inc.
keywords: hepatocellular carcinoma | immunotherapy | signaling pathways | targeted
  therapy
automl_pathway: 0.9348267
figid_alias: PMC10838672__F2
figtype: Figure
redirect_from: /figures/PMC10838672__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10838672__MCO2-5-e474-g005.html
  '@type': Dataset
  description: RTKs and its related downstream signaling pathways and their targeted
    therapies for hepatocellular carcinoma. The binding of RTKs to their corresponding
    growth factors can activate their protein kinase function, thereby regulating
    the downstream signal transduction pathways, expanding signal transduction and
    activating a series of biochemical reactions in cells. RTKIs are a hot spot in
    the research and development of antitumor drugs. At present, a variety of RTKIs
    related to HCC have entered phases I–III clinical trials and clinical use. EGFR,
    epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; HGF,
    hepatocyte growth factor;c‐Met, cellular mesenchymal epithelial transition factor;
    IGFR, insulin‐like growth factor receptor; PDGFR, platelet‐derived growth factor
    receptor; RTKs, receptor tyrosine kinases; RTKIs, receptor tyrosine kinase inhibitors;
    PTEN, phosphatase and tensin homolog; PI3K, phosphoinositide 3 kinase
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - IGF1
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - EGF
  - HGF
  - IL6
  - SOS1
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - TGFA
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - KDR
  - FLT1
  - FLT4
  - IGF1R
  - EGFR
  - PDGFRB
  - PDGFRA
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - MET
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - EPHB2
  - MAPK1
  - MAPK3
  - KRAS
  - HRAS
  - NRAS
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - JAK2
  - PTEN
  - AKT1
  - AKT2
  - AKT3
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - MTOR
  - Sorafenib
  - Lenvatinib
  - Gefitinib
  - Afatinib
  - Osimertinib
  - Erlotinib
  - Regorafenib
  - Linsitinib
  - Capmatinib
  - EGF
  - Selumetinib
  - PD0325901
  - RAS
  - MEK
  - Nucleus
---
